Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial.
Pettitt AR, Jackson R, Cicconi S, Polydoros F, Yap C, Dodd J, Bickerstaff M, Stackpoole M, Khan UT, Carruthers S, Oates M, Lin K, Coupland SE, Menon G, Kalakonda N, McCarthy H, Bloor A, Schuh A, Duncombe A, Dearden C, Fegan C, Kennedy B, Walewska R, Marshall S, Fox CP, Hillmen P.
Pettitt AR, et al. Among authors: polydoros f.
Haematologica. 2020 Dec 1;105(12):2868-2871. doi: 10.3324/haematol.2019.230805.
Haematologica. 2020.
PMID: 33256390
Free PMC article.
No abstract available.